[{"edinetCode":"E34965","endDate":"2019\/6\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2019\/8\/9","stockCode":4931,"accountingYear":null,"accountingYearStart":"2018\/10\/1","accountingYearEnd":"2019\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2019\/9\/30","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":17659300.0,"sharesOwendPercent":0.8171,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2019\/12\/23","stockCode":4931,"accountingYear":"第31期(自　平成30年10月１日　至　令和元年９月30日)","accountingYearStart":"2018\/10\/1","accountingYearEnd":"2019\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2019\/12\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/2\/10","stockCode":4931,"accountingYear":null,"accountingYearStart":"2019\/10\/1","accountingYearEnd":"2020\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2020\/3\/31","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":17777800.0,"sharesOwendPercent":0.8226,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2020\/5\/14","stockCode":4931,"accountingYear":null,"accountingYearStart":"2019\/10\/1","accountingYearEnd":"2020\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2020\/6\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/8\/12","stockCode":4931,"accountingYear":null,"accountingYearStart":"2019\/10\/1","accountingYearEnd":"2020\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2020\/9\/30","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":18037100.0,"sharesOwendPercent":0.842,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2020\/12\/24","stockCode":4931,"accountingYear":"第32期(自　令和元年10月１日　至　令和２年９月30日)","accountingYearStart":"2019\/10\/1","accountingYearEnd":"2020\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2020\/12\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/2\/10","stockCode":4931,"accountingYear":null,"accountingYearStart":"2020\/10\/1","accountingYearEnd":"2021\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2021\/3\/31","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":15649629.0,"sharesOwendPercent":0.7218,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2021\/5\/13","stockCode":4931,"accountingYear":null,"accountingYearStart":"2020\/10\/1","accountingYearEnd":"2021\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2021\/6\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.757,"cashAndCashEquivalents":null,"assets":20905000000.0,"currentAssets":16293000000.0,"fixedAsset":4611000000.0,"tangibleFixedAssets":2184000000.0,"intangibleFixedAssets":1472000000.0,"investmentAndOtherAssets":955000000.0,"liabilities":4929000000.0,"currentLiabilities":3740000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":173000000.0,"fixedLiabilities":1188000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":714000000.0,"netAsset":15976000000.0,"capitalStock":15819000000.0,"capital":4158000000.0,"capitalSurplus":4150000000.0,"accumulatedEarnings":7839000000.0,"treasuryStock":-329000000.0,"valuationAndConversionAdjustments":0.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":25289000000.0,"costOfSales":3893000000.0,"grossProfit":21395000000.0,"sgaExpenses":18981000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":2400000000.0,"nonOperatingIncome":59000000.0,"nonOperatingExpenses":39000000.0,"interestExpense":null,"ordinaryProfit":2419000000.0,"extraordinaryGain":null,"extraordinaryLoss":37000000.0,"incomeBeforeTax":2381000000.0,"incomeTaxes":757000000.0,"netIncome":1624000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1624000000.0,"comprehensiveIncome":1624000000.0,"eps":75.24,"dilutedEps":74.5,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/8\/11","stockCode":4931,"accountingYear":null,"accountingYearStart":"2020\/10\/1","accountingYearEnd":"2021\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2021\/9\/30","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":309.0,"averageTemporaryStaff":178.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":15265529.0,"sharesOwendPercent":0.7132,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":747.07,"equityRatio":0.689,"cashAndCashEquivalents":13652000000.0,"assets":23197000000.0,"currentAssets":18528000000.0,"fixedAsset":4669000000.0,"tangibleFixedAssets":2157000000.0,"intangibleFixedAssets":1435000000.0,"investmentAndOtherAssets":1075000000.0,"liabilities":7023000000.0,"currentLiabilities":4712000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":398000000.0,"fixedLiabilities":2311000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1839000000.0,"netAsset":16174000000.0,"capitalStock":15990000000.0,"capital":4158000000.0,"capitalSurplus":4150000000.0,"accumulatedEarnings":8532000000.0,"treasuryStock":-852000000.0,"valuationAndConversionAdjustments":0.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":33899000000.0,"costOfSales":5439000000.0,"grossProfit":28460000000.0,"sgaExpenses":25032000000.0,"salaryAndBenefit":null,"depreciationAndSGA":377000000.0,"RDExpenses":null,"operatingIncome":3424000000.0,"nonOperatingIncome":75000000.0,"nonOperatingExpenses":85000000.0,"interestExpense":1000000.0,"ordinaryProfit":3414000000.0,"extraordinaryGain":null,"extraordinaryLoss":12000000.0,"incomeBeforeTax":3401000000.0,"incomeTaxes":1083000000.0,"netIncome":2317000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2317000000.0,"comprehensiveIncome":2317000000.0,"eps":107.45,"dilutedEps":106.43,"dividendPerShare":null,"per":17.6,"roe":0.145,"cashFlowFromOperatingActivities":2071000000.0,"depreciationAndCashflowFromOperatingActivities":396000000.0,"cashFlowFromInvestingActivities":-1359000000.0,"cashFlowFromFinancialActivities":672000000.0,"changesInCashAndCashEquivalents":1380000000.0,"列1":"asr","submitDate":"2021\/12\/23","stockCode":4931,"accountingYear":"第33期(自　令和２年10月１日　至　令和３年９月30日)","accountingYearStart":"2020\/10\/1","accountingYearEnd":"2021\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0},{"edinetCode":"E34965","endDate":"2021\/12\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.709,"cashAndCashEquivalents":null,"assets":22419000000.0,"currentAssets":17747000000.0,"fixedAsset":4671000000.0,"tangibleFixedAssets":2142000000.0,"intangibleFixedAssets":1473000000.0,"investmentAndOtherAssets":1056000000.0,"liabilities":6377000000.0,"currentLiabilities":4154000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":398000000.0,"fixedLiabilities":2222000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1744000000.0,"netAsset":16041000000.0,"capitalStock":15899000000.0,"capital":4158000000.0,"capitalSurplus":4136000000.0,"accumulatedEarnings":8387000000.0,"treasuryStock":-784000000.0,"valuationAndConversionAdjustments":-3000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":9273000000.0,"costOfSales":1662000000.0,"grossProfit":7610000000.0,"sgaExpenses":6784000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":825000000.0,"nonOperatingIncome":9000000.0,"nonOperatingExpenses":3000000.0,"interestExpense":1000000.0,"ordinaryProfit":831000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":12000000.0,"incomeBeforeTax":819000000.0,"incomeTaxes":271000000.0,"netIncome":547000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":547000000.0,"comprehensiveIncome":544000000.0,"eps":25.56,"dilutedEps":25.35,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2022\/2\/9","stockCode":4931,"accountingYear":null,"accountingYearStart":"2021\/10\/1","accountingYearEnd":"2022\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E34965","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3826,"settlementDate":"2022\/9\/30","submitterName":"新日本製薬株式会社","submitterNameEnglish":"Shinnihonseiyaku Co., Ltd.","submitterNameKana":"シンニホンセイヤクカブシキガイシャ","location":"福岡市中央区大手門一丁目４番７号","industory":"化学","corporateNumber":5290000000000.0}]